INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 43 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,339,000 | -59.6% | 1,700,000 | -50.0% | 0.26% | -12.5% |
| Q2 2017 | $3,315,000 | +4.3% | 3,400,000 | 0.0% | 0.30% | -21.2% |
| Q1 2017 | $3,179,000 | -11.8% | 3,400,000 | -15.0% | 0.38% | -8.7% |
| Q4 2016 | $3,605,000 | +114.3% | 4,000,000 | +166.7% | 0.41% | +79.6% |
| Q3 2016 | $1,682,000 | – | 1,500,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 12,851,000 | $12,016,000 | 2.95% |
| Context Capital Management, LLC | 3,000,000 | $2,804,000 | 2.24% |
| Man Investments (CH) AG | 3,000,000 | $2,798,000 | 1.76% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 42,500,000 | $39,540,000 | 1.52% |
| MACKAY SHIELDS LLC | 17,069,000 | $15,982,000 | 0.73% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 73,035,000 | $68,425,000 | 0.63% |
| WOLVERINE ASSET MANAGEMENT LLC | 42,307,000 | $39,554,000 | 0.61% |
| LINDEN ADVISORS LP | 14,122,000 | $13,194,000 | 0.49% |
| GLG LLC | 9,100,000 | $8,486,000 | 0.47% |
| Jabre Capital Partners S.A. | 3,400,000 | $3,179,000 | 0.38% |